ICI Development Services for Bladder Cancer

Inquiry

Bladder cancer is a prevalent disease, and the treatment options for advanced bladder cancer remain limited. However, immune checkpoint inhibitors (ICIs) have demonstrated promising results in managing bladder cancer. At Alfa Cytology, we specialize in providing comprehensive ICI development services for bladder cancer.

Introduction to ICI

Immune checkpoints are regulatory pathways in the immune system that maintain self-tolerance and modulate the duration and amplitude of immune responses. Key immune checkpoint proteins include cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1). Immune checkpoints play a crucial role in preventing autoimmunity by downregulating immune responses.

PD-1/PD-L1 Pathway

Inhibits T cell activation and promotes tumor immune evasion.

CTLA-4 Pathway

Competes with CD28 for binding to B7 molecules, inhibiting T cell activation.

TIM-3 and LAG-3 Pathways

Emerging checkpoint proteins that contribute to T cell exhaustion.

Fig.1 Overview of TAMs for cancer treatment. (van Dorp, J., et al., 2023) Fig.1 Model of immune phenotypes in the bladder tumor immune microenvironment. (van Dorp, J., et al., 2023)

Research Hotspots of ICI Development

Bladder cancer often exploits immune checkpoints to evade immune surveillance. ICIs targeting these checkpoints have shown significant clinical efficacy, making them a cornerstone of bladder cancer immunotherapy.

Drug Name	Mechanism of Action	Development Stage	Company
Nivolumab	Anti-PD-1 Antibody	Approved	Bristol-Myers Squibb
Avelumab	Anti-PD-L1 Antibody	Approved	Merck/Pfizer
Durvalumab	Anti-PD-L1 Antibody	Phase III	AstraZeneca
Tremelimumab	Anti-CTLA-4 Antibody	Phase III	AstraZeneca

Our Services

Through cutting-edge research and advanced technology, Alfa Cytology delves into the intricate mechanisms underlying immune checkpoint action, enabling us to assist clients in developing groundbreaking ICI therapies while optimizing their efficacy and identifying crucial biomarkers. Our expertise accelerates the progress of novel bladder cancer therapy.

Target Identification and Validation

We employ advanced screening technologies
to identify checkpoint targets, validate biomarkers for ICI modulation, and use bladder cancer cell lines and animal models to validate ICI targets.

Antibody Development

Our services include producing monoclonal antibodies targeting checkpoint proteins (e.g., PD-1, PD-L1, CTLA-4), optimizing these antibodies for increased affinity and specificity, and assessing their ability to modulate immune checkpoint activity.

Combination Therapies

We design combination therapies that include ICIs and other therapeutic agents, evaluate the synergistic effects in bladder cancer models, and support the translation of combination therapies from preclinical to clinical development.

Preclinical Testing and Evaluation

We conduct in vitro and in vivo studies to evaluate the therapeutic potential of ICIs, perform comprehensive safety and toxicity testing in relevant preclinical models, and analyze pharmacokinetic and pharmacodynamic profiles.

Contact Us

At Alfa Cytology, we are dedicated to advancing the fight against bladder cancer through innovative and targeted therapeutic strategies. Our ICI development provide a seamless integration of state-of-the-art research and expert-driven solutions. If you are interested in developing ICI development for bladder cancer, please feel free to contact us.

Reference

van Dorp, J., & van der Heijden, M. S. The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. Frontiers in immunology, 2023, 14, 1235884.

For research use only. Not intended for any clinical use.

Related Services

Solutions

Inquiry

* Name:

* Email:

Phone:

* Services:

Description:

* Please note that we are not a pharmacy or clinic, so we do not offer diagnostic and treatment services for patients.

* Tick to confirm the Research Use Only (RUO) statement.